Find Aspirin Lysinate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Dl-lysine acetylsalicylate, 62952-06-1, Aspegic, Egicalm, Aspirisine, Aspidol
Molecular Formula
C15H22N2O6
Molecular Weight
326.34  g/mol
InChI Key
JJBCTCGUOQYZHK-UHFFFAOYSA-N
FDA UNII
2JJ274J145

Aspirin Lysinate
Aspirin DL-Lysine is the lysine salt form of acetylsalicylic acid, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic and anti-inflammatory activities. Like other NSAIDs, aspirin DL-lysine inhibits the activity of cyclooxygenase I and II, resulting in decreased formation of prostaglandins (PGs) and thromboxanes precursors. This leads to decreased PG synthesis by PG synthase. This agent also causes a decrease in the formation of thromboxane A2 synthesis by thromboxane synthase, thereby inhibiting platelet aggregation.
1 2D Structure

Aspirin Lysinate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-acetyloxybenzoic acid;2,6-diaminohexanoic acid
2.1.2 InChI
InChI=1S/C9H8O4.C6H14N2O2/c1-6(10)13-8-5-3-2-4-7(8)9(11)12;7-4-2-1-3-5(8)6(9)10/h2-5H,1H3,(H,11,12);5H,1-4,7-8H2,(H,9,10)
2.1.3 InChI Key
JJBCTCGUOQYZHK-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(=O)OC1=CC=CC=C1C(=O)O.C(CCN)CC(C(=O)O)N
2.2 Other Identifiers
2.2.1 UNII
2JJ274J145
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Acetylsalicylic Acid Lysinate

2. Aspegic

3. Aspirin Lysinate

4. Aspirin Lysine

5. Aspiryl-polylysine

6. Aspisol

7. Asprin Dl-lysine

8. Flectadol

9. L-lysine, 2-(acetyloxy)benzoate (1:1)

10. Lysine Acetylsalicylate

11. Lysine-acetylsalicylic Acid

12. Lysine-aspirin

13. Solusprin

14. Solusprin, Monosalicylate, (dl-lys)-isomer

15. Solusprin, Monosalicylate, (l-lys)-isomer

16. Venopirin

2.3.2 Depositor-Supplied Synonyms

1. Dl-lysine Acetylsalicylate

2. 62952-06-1

3. Aspegic

4. Egicalm

5. Aspirisine

6. Aspidol

7. Solpirin

8. Venopirin

9. Vetalgine

10. Dl-lysine-acetylsalicylate

11. Flectadol

12. Laspal

13. L-lysine Acetylsalicylate

14. Lysine Acetylsalicylic Acid

15. Asl

16. Lysine Acetylsalicylate,(s)

17. Schembl25877

18. 2-acetoxybenzoic Acid (1:1)

19. Lysine Aspirin [mart.]

20. Chembl1697753

21. Dtxsid50886518

22. Bcp12010

23. Lysine Acetylsalicylate [mi]

24. Akos025402349

25. 2,6-diaminohexanoic Acid Compound With

26. Ac-8243

27. Dl-lysine Acetylsalicylate, Aldrichcpr

28. Acetylsalicylate Lysine [who-dd]

29. Ft-0670894

30. Dl-lysine Acetylsalicylate [ep Monograph]

31. 952l061

32. Q15041214

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 326.34 g/mol
Molecular Formula C15H22N2O6
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count8
Rotatable Bond Count8
Exact Mass326.14778643 g/mol
Monoisotopic Mass326.14778643 g/mol
Topological Polar Surface Area153 Ų
Heavy Atom Count23
Formal Charge0
Complexity318
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Analgesics

Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)


Anti-Inflammatory Agents, Non-Steroidal

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)


Cyclooxygenase Inhibitors

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)


Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty